Open Orphan Plc stock analysis
Want to see GB:HVO full AI Analyst Report?
Open Orphan Plc (HVO) Share Price & Analysis
HVO Stock Chart & Stats
- Day’s Range
- GBX 4.93 - GBX 5.30
- 52-Week Range
- GBX 4.31 - GBX 11.00
- Previous Close
- GBX 5.20
- Volume
- N/A
- Average Volume (3M)
- 1.24M
- Market Cap
- GBP 34.76M
- Enterprise Value
- GBP 47.72M
- Total Cash (Recent Filing)
- GBP 12.98M
- Total Debt (Recent Filing)
- GBP 13.92M
- Price to Earnings (P/E)
- ―
- Beta
- 1.03
- Next Earnings
- Apr 14, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- May 15, 2025
- Dividend Yield
- 3.96%
Bulls Say, Bears Say
Bulls Say
Record Order Book
The record order book provides revenue visibility beyond the immediate reporting period and into 2027 and 2028. Combined with a 45% increase in proposals and 26% growth in proposal value, it supports the prospect of renewed demand and a stronger medium-term workload.
Differentiated Clinical Platform
Rapid study execution, dedicated recruitment infrastructure and infectious-disease expertise can differentiate hVIVO from conventional research approaches. These capabilities may support customer retention, defend its specialist market position and help convert growing demand for challenge studies into repeat business.
Broader Service Offering
A broader end-to-end offering increases the addressable customer base and creates more opportunities to capture revenue across a drug program. Supporting clients at multiple development stages can deepen relationships, improve cross-selling and reduce reliance on any single service line.
Bears Say
Sharp Profitability Deterioration
The latest annual results show that the earnings profile has become materially weaker and more volatile. Negative gross profit and a sizable net loss reduce internal funding capacity, make recovery dependent on execution, and weaken the financial cushion available for continued investment.
Significant Cash Burn
A reversal from positive cash generation to deep cash outflow increases reliance on existing liquidity or external funding if trading remains weak. Sustained cash burn could constrain investment, reduce strategic flexibility and make the company more exposed to further delays in customer project delivery.
Contract Delays And Margin Pressure
Deferred projects weaken near-term revenue conversion even though management describes them as delayed rather than canceled. The lower-margin second-half mix further limits earnings recovery, while uncertainty over timing and service mix makes sustained profitability harder to forecast.
HVO FAQ
What was Open Orphan Plc’s price range in the past 12 months?
What is Open Orphan Plc’s market cap?
When is Open Orphan Plc’s upcoming earnings report date?
How were Open Orphan Plc’s earnings last quarter?
Is Open Orphan Plc overvalued?
Does Open Orphan Plc pay dividends?
What is Open Orphan Plc’s EPS estimate?
How many shares outstanding does Open Orphan Plc have?
What happened to Open Orphan Plc’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Open Orphan Plc?
What is the TipRanks Smart Score and how is it calculated?
Open Orphan Plc Stock Smart Score
Company Description
Open Orphan Plc
hVIVO plc (HVO) operates as a premier full-service Contract Research Organisation (CRO) focused on early-phase clinical development, globally recognized as the leader in human challenge trials. The company provides a complete spectrum of clinical development services to a wide-ranging and growing client base, which includes seven of the world's ten largest biopharmaceutical companies. A key specialisation for hVIVO is orchestrating human challenge trials across numerous infectious and respiratory diseases, utilising its advanced, London-based quarantine facility, the largest of its kind globally. Additionally, the company offers extensive virology and immunology laboratory services through its hLAB division. Through its German subsidiary, CRS, hVIVO manages a 120-bed capacity across sites in Mannheim and Kiel, delivering early-phase clinical trial expertise, including first-in-human and proof-of-concept studies. Its other subsidiary, Venn Life Sciences, contributes to the biopharma sector by providing specialist early drug development consulting and biometry services. The Group collectively offers integrated drug development solutions, covering stages from preclinical research up to Phase II trials, supported by patient recruitment via FluCamp. Moreover, its five clinical sites facilitate outpatient Phase II and III trials, ensuring a streamlined and effective transition from drug discovery to late-stage development.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Yamin Mohammed Khan
- Employees
- 376
- Website
- www.hvivo.com
- Address
- 40 Bank Street, London, GL, E14 5NR, GB
Open Orphan Plc (HVO) Earnings & Revenues
HVO Earnings Call
Earnings Call SentimentPositive
The call was positive overall despite weak first-half financial results, a GBP 47 million full-year revenue outlook below consensus, contract delays and an expected full-year EBITDA loss. Management emphasized record order-book levels, a recovering human challenge trial pipeline, 110% laboratory revenue growth, diversification into new therapeutic areas and an immediately accretive CRS Berlin acquisition. The deferred contracts were explicitly described as delayed rather than canceled, and management expressed confidence in significant growth and positive EBITDA in 2027.
View all GB:HVO earnings summariesHVO Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 14 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |










